BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31269226)

  • 1. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.
    Raja SM; Sanders DB; Juel VC; Harati Y; Smith AG; Pascuzzi R; Richman DP; Wu A; Aleš KL; Jacobus LR; Jacobus DP; Guptill JT;
    Muscle Nerve; 2019 Sep; 60(3):292-298. PubMed ID: 31269226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of the triple-timed up-and-go test.
    Sanders DB; Guptill JT; Aleš KL; Hobson-Webb LD; Jacobus DP; Mahmood R; Massey JM; Pittman MM; Prather K; Raja SM; Yow E; Juel VC
    Muscle Nerve; 2018 Jan; 57(1):136-139. PubMed ID: 28545168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
    Sanders DB; Juel VC; Harati Y; Smith AG; Peltier AC; Marburger T; Lou JS; Pascuzzi RM; Richman DP; Xie T; Demmel V; Jacobus LR; Aleš KL; Jacobus DP;
    Muscle Nerve; 2018 Apr; 57(4):561-568. PubMed ID: 29280483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
    Thakkar N; Guptill JT; Aleš K; Jacobus D; Jacobus L; Peloquin C; Cohen-Wolkowiez M; Gonzalez D;
    CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):625-634. PubMed ID: 28623849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
    Schneider I; Kornhuber ME; Hanisch F
    J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome.
    Portaro S; Parisi D; Polizzi A; Ruggieri M; Andreetta F; Bernasconi P; Toscano A; Rodolico C
    J Child Neurol; 2014 Sep; 29(9):NP58-61. PubMed ID: 24114606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
    Lee MK; Sunwoo IN; Kim SM
    J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
    Mantegazza R
    Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
    [No Abstract]   [Full Text] [Related]  

  • 12. [Autoimmune myasthenia and Lambert-Eaton myasthenic syndrome. Physiopathologic concepts].
    Eymard B
    Ann Med Interne (Paris); 1989; 140(6):462-6. PubMed ID: 2696402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
    Chan KY; Chang RS; Lau VW; Chan ML; Lai T
    Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies.
    Oh SJ
    Muscle Nerve; 2018 May; 57(5):E130. PubMed ID: 29406572
    [No Abstract]   [Full Text] [Related]  

  • 15. Lambert Eaton myasthenic syndrome.
    Petty R
    Pract Neurol; 2007 Aug; 7(4):265-7. PubMed ID: 17636143
    [No Abstract]   [Full Text] [Related]  

  • 16. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome].
    Boutin E; Rey C; Romeu M; Pouget J; Franques J
    Rev Med Interne; 2013 Aug; 34(8):493-6. PubMed ID: 23759215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis Lambert-Eaton overlap syndrome.
    Oh SJ
    Muscle Nerve; 2016 Jan; 53(1):20-6. PubMed ID: 26418033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lambert-Eaton myasthenic syndrome in childhood.
    Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
    McEvoy KM; Windebank AJ; Daube JR; Low PA
    N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].
    Uekita K; Ishida T; Sekine S; Ishii T; Sato S; Sugawara A; Tachihara M; Watanabe K; Kanazawa K; Saito J; Tanino Y; Munakata M
    Nihon Kokyuki Gakkai Zasshi; 2009 Jan; 47(1):76-80. PubMed ID: 19198242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.